FGD4: A Protein Involved in Multiple Cellular Signaling Pathways

Target Name: FGD4

NCBI ID: G121512

FGD4

FGD4: A Protein Involved in Multiple Cellular Signaling Pathways

FGD4 (FYVE, RhoGEF and PH domain containing 4, transcript variant 3) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the G-protein-coupled receptor (GPCR) family and is involved in the regulation of cellular signaling pathways.

FGD4 has been identified as a potential drug target due to its involvement in several diseases, including heart failure, hypertension, and diabetes. It is also been shown to be overexpressed in various types of cancer, which suggests that it may have potential as a biomarker for cancer.

One of the unique features of FGD4 is its ability to interact with multiple GPCR signaling pathways. It has been shown to interact with the GPCR signaling pathway, which involves the regulation of cellular signaling by the neurotransmitter GABA. Additionally, FGD4 has been shown to interact with the TGF-β signaling pathway, which is involved in the regulation of cell growth and differentiation.

FGD4 is also involved in the regulation of ion channels, which are responsible for the flow of electrical current through cells. This is important for the proper function of many cellular processes, including muscle contractions and nerve signals.

One of the challenges in studying FGD4 is its high level of expression in various tissues, which can make it difficult to study its effects in specific contexts. However, research into its role in diseases such as heart failure and hypertension has shown that it may have potential as a drug target.

In addition to its potential as a drug target, FGD4 is also a potential biomarker for cancer. Its overexpression in various types of cancer has been shown to be associated with a number of unfavorable outcomes, including the development of cancer-related metastases.

FGD4 is also involved in the regulation of cellular signaling pathways that are important for the development and progression of cancer. For example, it has been shown to be involved in the regulation of the angiogenesis pathway, which is the process by which new blood vessels are formed to supply tumors with oxygen and nutrients.

In conclusion, FGD4 is a protein that has been shown to be involved in a number of cellular signaling pathways that are important for the regulation of many different cellular processes. Its potential as a drug target and biomarker make it an attractive target for further research. Further studies are needed to fully understand its role in the regulation of cellular signaling pathways and its potential as a drug and biomarker.

Protein Name: FYVE, RhoGEF And PH Domain Containing 4

Functions: Activates CDC42, a member of the Ras-like family of Rho- and Rac proteins, by exchanging bound GDP for free GTP. Plays a role in regulating the actin cytoskeleton and cell shape. Activates MAPK8 (By similarity)

The "FGD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FGD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets